These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39153810)

  • 1. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Shin H; Lee JH
    Lancet; 2024 Aug; 404(10453):654-655. PubMed ID: 39153810
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Donadon M; Di Martino M; Rigamonti C
    Lancet; 2024 Aug; 404(10453):655-656. PubMed ID: 39153812
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Chen Z; Lan X; Du C; Xiao H
    Lancet; 2024 Aug; 404(10453):656. PubMed ID: 39153813
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.
    Rose S; Ashraf MU; Premkumar M
    Lancet; 2024 Aug; 404(10453):656-657. PubMed ID: 39153814
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial - Authors' reply.
    Chow PKH; Hack SP; Spahn JH; Yopp AC
    Lancet; 2024 Aug; 404(10453):657-658. PubMed ID: 39153815
    [No Abstract]   [Full Text] [Related]  

  • 6. Pursuing efficacious systemic therapy for hepatocellular carcinoma.
    Cheng AL
    Nat Rev Gastroenterol Hepatol; 2021 Feb; 18(2):95-96. PubMed ID: 33408363
    [No Abstract]   [Full Text] [Related]  

  • 7. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

  • 8. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
    Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
    Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
    [No Abstract]   [Full Text] [Related]  

  • 9. Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future.
    Singal AG; Yarchoan M; Yopp A; Sapisochin G; Pinato DJ; Pillai A
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38829199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy.
    Rizzo A; Ricci AD; Brandi G
    Future Oncol; 2021 Mar; 17(7):755-757. PubMed ID: 33508960
    [No Abstract]   [Full Text] [Related]  

  • 11. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
    Chen SC; Chao Y; Yang MH
    Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
    Kikuchi T; Takeuchi Y; Nouso K; Kariyama K; Kuwaki K; Toshimori J; Iwado S; Moriya A; Hagihara H; Takabatake H; Tada T; Yasunaka T; Sakata M; Sue M; Miyake N; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A; Otsuka M
    Liver Int; 2024 Jul; 44(7):1736-1737. PubMed ID: 38717049
    [No Abstract]   [Full Text] [Related]  

  • 14. New systemic agents for hepatocellular carcinoma: an update 2020.
    von Felden J
    Curr Opin Gastroenterol; 2020 May; 36(3):177-183. PubMed ID: 32101985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen F; Huang P; Wu Q; Yang Y; Zhou K; Zhang M; Li Q
    Cancer Med; 2024 Aug; 13(16):e70094. PubMed ID: 39149756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
    Tsilimigras DI; Moris D
    J BUON; 2021; 26(2):637. PubMed ID: 34077021
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma.
    Allaire M; Avila MA
    Liver Int; 2024 Jun; 44(6):1276-1277. PubMed ID: 38775365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.